Mesenchymal stem cells as a potential therapy for COVID-19

Liu, Shan; Peng, Dan-Yi; Qiu, Huijun; Yang, Ke; Fu, Zhou; Zou, Lin

doi:10.1186/s13287-020-01678-8

Cited by 65 publications

(63 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mesenchymal stem cells (MSC) possess potent immunomodulatory activities [47]. Several in vivo studies in animal models and ex vivo human lung models have proven that MSC can prevent lung injury, reduce inflammation, regulate immune responses, and foster alveolar fluid clearance [47]. Moreover, MSC secrete antimicrobial and painkiller molecules [47].…”

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

“…Several in vivo studies in animal models and ex vivo human lung models have proven that MSC can prevent lung injury, reduce inflammation, regulate immune responses, and foster alveolar fluid clearance [47]. Moreover, MSC secrete antimicrobial and painkiller molecules [47]. The in vivo safety of in vivo local and intravenous administration of MSC has been demonstrated in multiple human clinical trials, including studies of ARDS [47].…”

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

See 1 more Smart Citation

Weathering the Cytokine Storm in COVID-19: Therapeutic Implications

et al. 2020

View full text Add to dashboard Cite

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recently emerged in Wuhan, Hubei-China, as responsible for the coronavirus disease 2019 (COVID-19) and then spread rapidly worldwide. While most individuals remain asymptomatic or develop only mild symptoms, approximately 5% develop severe forms of COVID-19 characterized by acute respiratory distress syndrome (ARDS) and multiple-organ failure (MOF) that usually require intensive-care support and often yield a poor prognosis. Summary: The pathophysiology of COVID-19 is far from being completely understood, and the lack of effective treatments leads to a sense of urgency to develop new therapeutic strategies based on pathophysiological assumptions. The exaggerated cytokine release in response to viral infection, a condition known as cytokine release syndrome (CRS) or cytokine storm, is emerging as the mechanism leading to ARDS and MOF in COVID-19, thus endorsing the hypothesis that properly timed

show abstract

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

Weathering the Cytokine Storm in COVID-19: Therapeutic Implications

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Current COVID-19 data (https://www.worldometers.info/coronavirus/) indicates that a substantial portion (∼2%) of coronavirus-affected people develops severe or critical symptoms. The inclusion criteria for critically ill COVID-19 patients include respiratory rate ≥30 times/min, pulse oxygen saturation at rest ≤93%, the partial pressure of PaO 2 / FiO 2 ≤ 300 mmHg, a requirement for mechanical ventilation and shock (S. Liu et al, 2020). Such critically ill COVID-19 patients may require alternative therapeutic treatment options for better recovery.…”

Section: Potential Groups Of Covid-19 Patients For Stem Cell Therapymentioning

confidence: 99%

“…Stem cell-based regenerative therapies were initiated recently in China (Leng et al, 2020;Liang et al, 2020) and approval of Emergency Use Authorization (EUA) of stem cell use by FDA for COVID-19 patients has created an excitement among the medical community. (Harrell, Sadikot, & Pascual, 2019) and thus are able to alter the innate and adoptive immune responses (S. Liu, Peng, & Qiu, 2020). MSCs were used previously for the treatment of graft vs host diseases (GvHDs) as well as for the treatment of other virusassociated diseases such as immunologic abnormality in human immunodeficiency virus, chronic hepatitis in hepatitis B virus, and acute lung injury in influenza virus (Maytawan, Suradej, & Arunee, 2015).…”

mentioning

confidence: 99%

“…MSCs possess powerful anti-inflammatory and immunomodulatory properties and therefore can also control cytokine storms by inhibiting overactivation of the immune systemand by improving endogenous repair of injured tissues(Leng et al, 2020). MSCs possess special immunoregulatory properties that enable these cells to modulate the functions of various immune cells(Harrell et al, 2019).MSCs are also able to alter the innate and adoptive immune responses (S Liu et al, 2020)…”

mentioning

confidence: 99%

See 1 more Smart Citation

Stem cell therapy for COVID‐19: Possibilities and challenges

Choudhery

Harris

2020

Cell Biology International

View full text Add to dashboard Cite

Since its eruption in China, novel coronavirus disease (COVID-19) has been reported in most of the countries and territories (>200) of the world with ∼18 million confirmed cases (as of August 3, 2020). In most of the countries, COVID-19 upsurge is uncontrolled with a significant mortality rate. Currently, no treatment effective for COVID-19 is available in the form of vaccines or antiviral drugs and patients are currently treated symptomatically. Although the majority of the patients develop mild symptoms and recover without mechanical ventilation for respiratory management, severe respiratory illness develops in a significant portion of affected patients and may result in death. While the scientific community is working to develop vaccines and drugs against the COVID-19 pandemic, novel alternative therapies may reduce the mortality rate. Recent use of stem cells for critically ill COVID-19 patients in a small group of patients in China and subsequent Emergency Use Authorization of stem cells by Food and Drug Administration to Global Institute of Stem Cell Therapy and Research and Athersys has created excitement among the medical community. As a result, several clinical trials have been registered using stem cells for COVID-19 treatment that aim to use different cell sources, dosage, and importantly diverse targeted patient groups. In this brief review, the possibilities of stem cell use in COVID-19 patients and relevant challenges in their use have been discussed.

show abstract

The critical role of mesenchymal stromal/stem cell therapy in COVID‐19 patients: An updated review

Ebrahimi

Rad

Zebardast

et al. 2021

Cell Biochemistry & Function

View full text Add to dashboard Cite

New coronavirus disease 2019 , as a pandemic disaster, has drawn the attention of researchers in various fields to discover suitable therapeutic approaches for the management of COVID-19 patients. Currently, there are many worries about the rapid spread of COVID-19; there is no approved treatment for this infectious disease, despite many efforts to develop therapeutic procedures for COVID-19. Emerging evidence shows that mesenchymal stromal/stem cell (MSC) therapy can be a suitable option for the management of COVID-19. These cells have many biological features (including the potential of differentiation, high safety and effectiveness, secretion of trophic factors and immunoregulatory features) that make them suitable for the treatment of various diseases. However, some studies have questioned the positive role of MSC therapy in the treatment of COVID-19. Accordingly, in this paper, we will focus on the therapeutic impacts of MSCs and their critical role in cytokine storm of COVID-19 patients.

show abstract

Mesenchymal stem cells as a potential therapy for COVID-19

Cited by 65 publications

References 20 publications

Weathering the Cytokine Storm in COVID-19: Therapeutic Implications

Weathering the Cytokine Storm in COVID-19: Therapeutic Implications

Stem cell therapy for COVID‐19: Possibilities and challenges

The critical role of mesenchymal stromal/stem cell therapy in COVID‐19 patients: An updated review

Contact Info

Product

Resources

About